Jump to content

ChromaDex: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
remove unreliable sources
SVG logo
 
(29 intermediate revisions by 14 users not shown)
Line 1: Line 1:
{{Short description|Food ingredient company in California}}
{{Infobox company
{{Infobox company
| name = ChromaDex, Inc
| name = ChromaDex, Inc
| logo = ChromaDexLogo2015.png
| logo = ChromaDex_logo.svg
| type = [[Public company|Public]]
| type = [[Public company|Public]]
| traded_as = {{NASDAQ|CDXC}}<br>[[Russell 2000 Index]] component
| traded_as = {{NASDAQ|CDXC}}<br />[[Russell 2000 Index]] component
| industry = [[Dietary supplements]], food ingredients
| industry = [[Dietary supplements]], food ingredients, chemical sample analysis
| foundation = 1999
| foundation = 1999
| location = [[Los Angeles, California]], United States
| location = [[Los Angeles, California]], United States
| key_people = [[Rob Fried]]<br><small>(CEO)</small><br>[[Frank Jaksch]]<br><small>([[Entrepreneur|Co-Founder]], Executive Chairman)</small>
| key_people = [[Rob Fried]]<br /><small>(CEO)</small><br />Frank Jaksch<br /><small>(Cofounder, Executive Chairman)</small>
| products = [[Tru Niagen]]
| products = Tru Niagen
| website = {{URL|https://www.chromadex.com/}}
| website = {{URL|https://www.chromadex.com/}}


}}
}}

'''ChromaDex''' is a [[dietary supplement]] and [[food ingredient]] company based in [[Los Angeles, California]] founded in 1999 that is publicly traded on the NASDAQ.
'''ChromaDex''' is a [[dietary supplement]] and [[food ingredient]] company based in [[Los Angeles, California]] founded in 1999 that is publicly traded on the NASDAQ.


In 2011, [[Dartmouth College]] announced it granted ChromaDex exclusive worldwide rights to a novel manufacturing process for [[nicotinamide riboside]] which it markets and sells as an ingredient under the brand name [[Tru Niagen]]. The firm also offers [[contract research organization|contract research]] services for sourcing [[raw materials]], identifying new compounds, and developing processes for large scale manufacturing.<ref name="PPT">{{cite web|url=http://www.otcmarkets.com/stock/CDXC/profile|title=OTC Markets Stock Profile CDXC|date=|publisher=|pages=|quote=|accessdate=2016-03-21|work=OTC Markets}}</ref> ChromaDex licensed patents from the University of Mississippi and the [[USDA]] to commercially develop [[pterostilbene]] and sell the compound trademarked as pTeroPure via the company's BluScience product line.<ref name="DM">{{cite web |url= http://thedmonline.com/article/ole-miss-grants-exclusive-patent-rights-chromadex-corp |title= Ole Miss grants exclusive patent rights to ChromaDex Corp. |accessdate=2012-05-25 |last=Neeb|first=Matthew |date=2011-06-20 |work= |publisher=The Daily Mississippian |pages= |quote= }}</ref> ChromaDex no longer sells PteroPure.{{cn|date=October 2019}}
In 2011, ChromaDex licensed patents from [[Dartmouth College]], [[Cornell University]], and [[Washington University in St. Louis]] regarding [[nicotinamide riboside]], which it markets and sells as an ingredient under the brand name Niagen. ChromaDex licensed patents from the University of Mississippi and the [[USDA]] to commercially develop [[pterostilbene]] and sell the compound under the brand name pTeroPure.<ref name="DM">{{cite web |url=http://thedmonline.com/article/ole-miss-grants-exclusive-patent-rights-chromadex-corp |title=Ole Miss grants exclusive patent rights to ChromaDex Corp. |accessdate=2012-05-25 |last=Neeb |first=Matthew |date=2011-06-20 |publisher=The Daily Mississippian |pages= |quote= |archive-url=https://web.archive.org/web/20120418075931/http://thedmonline.com/article/ole-miss-grants-exclusive-patent-rights-chromadex-corp |archive-date=2012-04-18 |url-status=dead }}</ref> ChromaDex no longer sells pTeroPure.<ref>{{Cite web|title=ChromaDex ceases new pterostilbene orders based on research demonstrating increase in LDL cholesterol|url=http://www.nutritionaloutlook.com/article/chromadex-ceases-new-pterostilbene-orders-based-research-demonstrating-increase-ldl|last=Krawiec|first=Sebastian|date=2018-10-31|website=Nutritional Outlook|language=en|access-date=2020-05-01}}</ref>


== History ==
[[Elysium Health]] bought the ingredients in its "Basis" product from ChromaDex.<ref name=Wired>{{cite news|last1=Zhang|first1=Sarah|title=The Weird Business Behind a Trendy "Anti-Aging" Pill|url=https://www.wired.com/2016/07/confused-elysiums-anti-aging-drug-yeah-fda/|work=Wired|date=July 6, 2016}}</ref> The two firms had an agreement under which Elysium didn't have to acknowledge ChromaDex as the source of the ingredients, but then after Elysium recruited the head of manufacturing from ChromaDex and stopped paying ChromaDex, ChromaDex sued Elysium and the information became public.<ref name=TC>{{cite news|last1=Buhr|first1=Sarah|title=A new lawsuit alleges anti-aging startup Elysium Health hasn’t paid its sole supplier|url=https://techcrunch.com/2017/01/16/a-new-lawsuit-alleges-anti-aging-startup-elysium-health-hasnt-paid-its-supplier-and-is-in-breach-of-agreement/|work=TechCrunch|date=January 16, 2017}}</ref>
Founded in 1999 by Frank Jaksch, ChromaDex first acquired licensed Dartmouth patents on nicotinamide riboside in 2012, leading to the commercialization of Niagen in 2013.  

ChromaDex is traded on the NASDAQ (as CDXC) as of April 2016 and was added to the U.S. Small Cap Russell 2000 Index in June 2018.  

In 2017, the company acquired HealthSpan Research LLC and its product Tru Niagen, a standalone nicotinamide riboside supplement, sold direct to U.S. consumers. Also in 2017, ChromaDex raised $48 million to support research and development.  


==References==
==References==
{{Reflist|33em}}
{{Reflist}}


==External links==
==External links==
* {{Official website|http://www.chromaDex.com}}
* {{Official website|http://www.chromaDex.com}}

{{Authority control}}


[[Category:Biotechnology companies of the United States]]
[[Category:Biotechnology companies of the United States]]

Latest revision as of 08:17, 19 October 2024

ChromaDex, Inc
Company typePublic
Nasdaq: CDXC
Russell 2000 Index component
IndustryDietary supplements, food ingredients, chemical sample analysis
Founded1999
HeadquartersLos Angeles, California, United States
Key people
Rob Fried
(CEO)
Frank Jaksch
(Cofounder, Executive Chairman)
ProductsTru Niagen
Websitewww.chromadex.com

ChromaDex is a dietary supplement and food ingredient company based in Los Angeles, California founded in 1999 that is publicly traded on the NASDAQ.

In 2011, ChromaDex licensed patents from Dartmouth College, Cornell University, and Washington University in St. Louis regarding nicotinamide riboside, which it markets and sells as an ingredient under the brand name Niagen. ChromaDex licensed patents from the University of Mississippi and the USDA to commercially develop pterostilbene and sell the compound under the brand name pTeroPure.[1] ChromaDex no longer sells pTeroPure.[2]

History

[edit]

Founded in 1999 by Frank Jaksch, ChromaDex first acquired licensed Dartmouth patents on nicotinamide riboside in 2012, leading to the commercialization of Niagen in 2013.  

ChromaDex is traded on the NASDAQ (as CDXC) as of April 2016 and was added to the U.S. Small Cap Russell 2000 Index in June 2018.  

In 2017, the company acquired HealthSpan Research LLC and its product Tru Niagen, a standalone nicotinamide riboside supplement, sold direct to U.S. consumers. Also in 2017, ChromaDex raised $48 million to support research and development.  

References

[edit]
  1. ^ Neeb, Matthew (2011-06-20). "Ole Miss grants exclusive patent rights to ChromaDex Corp". The Daily Mississippian. Archived from the original on 2012-04-18. Retrieved 2012-05-25.
  2. ^ Krawiec, Sebastian (2018-10-31). "ChromaDex ceases new pterostilbene orders based on research demonstrating increase in LDL cholesterol". Nutritional Outlook. Retrieved 2020-05-01.
[edit]
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=ChromaDex&oldid=1252007997"